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Allergic asthma is caused by Th2-cell-type cytokines
in response to allergen exposure. Type 2 innate
lymphoid cells (ILC2s) are a newly identified subset
of immune cells that, along with Th2 cells, contribute
to the pathogenesis of asthma by producing copious
amounts of IL-5 and IL-13, which cause eosinophilia
and airway hyperreactivity (AHR), a cardinal feature
of asthma. ILC2s express ICOS, a T cell costimulatory
molecule with a currently unknown function. Here we
showed that a lack of ICOS on murine ILC2s and
blocking the ICOS:ICOS-ligand interaction in human
ILC2s reduced AHR and lung inflammation. ILC2s ex-
pressed both ICOS and ICOS-ligand, and the ICOS:
ICOS-ligand interaction promoted cytokine produc-
tion and survival in ILC2s through STAT5 signaling.
Thus, ICOS:ICOS-ligand signaling pathway is criti-
cally involved in ILC2 function and homeostasis.
INTRODUCTION
Allergic asthma is a chronic inflammatory disease of the airways.
It is initiated by Th2-cell-type cytokines, including IL-5 and IL-13.
IL-5 plays an important role in the activation and recruitment of
eosinophils to the airways, and IL-13 increases goblet cell hyper-
plasia, mucus production, and the sensitivity of airway smooth-
muscle cells to stimuli and leads to airway hyperreactivity (AHR),
a cardinal feature of asthma. Like Th2 cells, type 2 innate
lymphoid cells (ILC2s) can rapidly produce large amounts of
Th2 cytokines (Hazenberg and Spits, 2014; Walker et al., 2013)
and therefore play an important role in the pathogenesis of
asthma.
ILC2shavebeendiscoveredas thesourceof IL-5and IL-13pro-
duction in alymphoid, recombination activating gene (RAG)-defi-
cient mice and can be activated by IL-25, IL-33, thymic stromal
lymphopoietin (TSLP), and fungal allergens such as Alternaria.538 Immunity 42, 538–551, March 17, 2015 ª2015 Elsevier Inc.They contribute to the pathogenesis of asthma and play a role in
maintaining airway epithelial integrity through the production of
amphiregulin (Barlow et al., 2012; Barlow et al., 2013; Bartemes
et al., 2012; Bartemes et al., 2014; Chang et al., 2011; Fallon
et al., 2006; Mjo¨sberg et al., 2011; Monticelli et al., 2011;
Moro et al., 2010; Neill et al., 2010; Teunissen et al., 2014).
ILC2s lack the expression of the markers that are associated
with previously identified immune lineages but express CD45,
CD90, and cytokine receptors IL2Ra, IL-7Ra, IL-33R, c-Kit
(mouse), and CRTH2 and CD161 (human) (Barlow et al., 2012;
Bartemeset al., 2012;Chang et al., 2011; Fallonet al., 2006;Mjo¨s-
berg et al., 2011; Monticelli et al., 2011; Moro et al., 2010; Neill
et al., 2010). ILC2s do not express RAG, and unlike T or B cells,
they act in a non-antigen-specificmanner; however, they express
inducible T cell costimulator (ICOS), which is an important costi-
mulatory molecule in T cells (Bartemes et al., 2012; Halim et al.,
2014; Hutloff et al., 1999; McAdam et al., 2001).
ICOS is related to the CD28 superfamily and is highly ex-
pressed on activated T cells (Hutloff et al., 1999) as well as reg-
ulatory T cells and is crucial for the survival and function of
T cells, Th2 cell differentiation and for lung inflammatory re-
sponses (Coyle et al., 2000; Dong et al., 2001; Gonzalo et al.,
2001; McAdam et al., 2000; Nurieva et al., 2003). Binding ICOS
to ICOS-ligand (ICOS-L) activates a cascade of intracellular
signaling molecules that prevent apoptosis and lead to the pro-
duction of cytokines such as IL-4 and IL-13 (Coyle et al., 2000;
Dong et al., 2001). To date, ICOS-L has been reported to be ex-
pressed by B cells, non-lymphoid cells, and lung epithelial cells
but not by T cells or innate lymphoid cells (Qian et al., 2006; Swal-
low et al., 1999; Watanabe et al., 2008) and is downregulated
upon binding to ICOS as an immunoregulatory mechanism (Wa-
tanabe et al., 2008). The functional requirement of ICOS for the
function and survival of ILC2 remains to be elucidated.
In this study we evaluated the functional requirement for ICOS
and its interaction with ICOS-L in cytokine production and ho-
meostasis of murine and human ILC2s. We found that human
and murine ILC2s express both ICOS and ICOS-L. Using
gene-deficient and humanized mice, we discovered that the
ICOS:ICOS-L interaction is crucial for the function and homeo-
static survival of ILC2s. We further showed that lack of the
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Figure 1. Icos–/– Mice Exhibit Reduced AHR, Inflammation, and Number of ILC2s in Response to Intranasal IL-33
BALB/cBYJ or Icos/ mice were intranasally challenged with recombinant mouse IL-33 or PBS on days 1–3, and measurement of lung function and sample
withdrawal followed on day 4.
(A and B) Lung resistance (A) and dynamic compliance (B) in response to increasing doses of inhaled methacholine.
(C) Total numbers of eosinophils in the BAL.
(D) Lung histology
(E) Flow-cytometry analysis of lung ILC2s in PBS-treated mice, as defined by a lack of expression of lineage markers (CD3e, CD45R, Gr-1, CD11c, CD11b,
Ter119, NK1.1, TCR-gd, and FCεRI) and expression of CD90, CD45, and ST2. Dot plots are gated on CD45+ single cells.
(G) Total number of ILC2s in the lungs of PBS- and IL-33-treatedWT and Icos/mice. Data are representative of three independent experiments, and bar-graphs
show data as means ± SEM (n = 5). Statistical significance is indicated as follows: **p < 0.01, Icos/ + IL33 compared to WT + IL33; *p < 0.05, Icos/ + IL33
compared to WT + IL33; ###p < 0.005 WT + IL-33 compared to WT + PBS; ##p < 0.01, WT + IL-33 compared to WT + PBS.ICOS:ICOS-L interaction alters the activation of transcription
factor STAT5. Our findings provide insight into the mechanisms
of induction of allergic asthma that could ultimately be used in
new therapeutic approaches that target the ICOS:ICOS-L
pathway in ILCs.
RESULTS
ICOS-DeficientMice ShowReduced IL-33-Induced AHR,
inflammation, and Number of ILC2s
We first addressed whether the expression of ICOS is required
for the function of ILC2s by comparing IL-33-induced AHR and
airway inflammation in Icos/ mice with that in wild-type (WT)
BALB/c mice. Mice received intranasal (i.n.) IL-33 (0.5 mg in
50 ml per mouse) or PBS (50 ml per mouse) on 3 consecutive
days. 1 day after the last i.n. challenge, lung function wasmeasured by direct measurement of lung resistance and dy-
namic compliance in anesthetized tracheostomized mice via
the FinePointe RC system (Buxco Research Systems), followed
by analysis of bronchial alveolar lavage (BAL) and the sampling
of lung tissue. As expected, i.n. administration of IL-33 signifi-
cantly increased lung resistance in WT and Icos/ mice (Fig-
ure 1A); however, lung resistance in IL-33-treated Icos/ mice
was significantly lower than that in IL-33-treated WT mice (Fig-
ure 1A), indicating that ICOS is required for IL-33-induced
AHR. In agreement with lung-resistance findings, the results of
dynamic compliance showed an improved response in IL-33-
treated Icos/ mice compared to IL-33-treated WT mice, but
they showed significantly lower dynamic compliance than their
PBS-treated counterparts (Figure 1B). IL-33 treatment signifi-
cantly increased the number of eosinophils in the BAL of WT
and Icos/ mice, although the number of eosinophils in theImmunity 42, 538–551, March 17, 2015 ª2015 Elsevier Inc. 539
BAL was reduced in IL-33-treated Icos/mice compared toWT
mice, indicating that IL-33-induced inflammation is impaired in
the absence of ICOS (Figures 1C and 1D).
IL-33 treatment significantly increased the total number of
ILC2s in WT and in Icos/ mice, but the number of ILC2s was
lower in Icos/ mice than in WT controls in PBS- and IL-33-
treated groups (Figures 1E and 1F). We also quantified the fre-
quency of ILC2s in the bone marrow, small intestine, and colon
and found that, similar to the findings in the lungs, the frequency
of ILC2s was significantly lower in the aforementioned organs in
Icos/ than in WTmice (Figure S1 in the Supplemental Informa-
tion available with this article online). These results suggest that
ICOS is important for the function and homeostasis of ILC2s.
A Lack of ICOS Increases Cell Death in ILC2s
Because we had found that the number of ILC2s was lower in
Icos/ mice, we investigated whether a lack of ICOS affects
the survival, proliferation, or migration capacities of ILC2s.
Icos/ and WT mice were challenged with i.n. rm-IL-33
(0.5 mg/mouse), and after 24 hr ILC2s were stained with dead-
cell-discrimination dye and annexin V so that cell death and
apoptosis could be assessed. The number of dead cells was
significantly increased in PBS-treated Icos/ mice compared
to PBS-treated WT mice (Figures 2A and 2B). Similarly, the
number of dead ILC2s after IL-33-administration was higher in
Icos/ than in WT mice (Figures 2A and 2B), whereas the
number of early-apoptotic and late-apoptotic ILC2s was
similar in both strains subjected to the same treatments. We
further analyzed the expression of anti-apoptotic factor BCL-2
and found that upon stimulation by IL-33, the expression of
BCL-2 inWT ILC2s was significantly increased (Figure 2C). Inter-
estingly, the expression of BCL-2 was significantly lower in
Icos/ than in WT ILC2s (Figure 2C). To evaluate whether a
lack of ICOS affects the proliferation rate of ILC2s, we examined
the expression of Ki-67 in WT and Icos/ ILC2s. The expression
levels of Ki-67 in the ILC2s of Icos/ mice treated with PBS- or
IL-33 were not significantly different from those of WT mice
treated the same way (Figure 2D). These data suggest that a
lack of ICOS impairs the survival of ILC2s rather than their
proliferation.
Because a reduced number of ILC2s in the absence of ICOS
could be caused by the altered migratory behavior of ILC2s,
we analyzed the expression of chemokine receptors CCR3,
CCR4, CXCR4, CCR6, and CCR7 and adhesion molecules
ICAM-I, ICAM-II, and Integrin b7 in Icos/ and WT ILC2s in
steady state and after IL-33 stimulation (Figure S2A). We found
that in steady state Icos/ ILC2s seem to express a higher level
of ICAM-II and a modestly lower level of CXCR4 than WT ILC2s.
After IL-33 stimulation, Icos/ ILC2s show amodest increase in
integrin b7 and CCR7 expression (Figure S2A).
A Lack of ICOS Impairs Cytokine Production by ILC2s
We next examined whether ICOS is required for the functional
production of cytokines by ILC2s. We measured intracellular cy-
tokines 24 hr after i.n. rm-IL33 administration and also measured
cytokines in the supernatant of in vitro cultures of purified ILC2s
for 24 and 48 hr. For intracellular staining, we used fixable dead-
cell-discrimination dye to assess the cytokine production specif-
ically in live ILC2s. Intracellular cytokine staining showed that540 Immunity 42, 538–551, March 17, 2015 ª2015 Elsevier Inc.production of IL-13 by ILC2s was lower in Icos/ than in WT
mice, whereas there was no difference in the production of
IL-5 between Icos/ and WT mice (Figures 2E and 2F). We did
not detect significant production of IL-4 or IL-17a by ILC2s. Inter-
estingly, we observed that the amount of IL-5 and IL-13 in the
supernatant of in-vitro-cultured purified ILC2s was significantly
lower in Icos/ ILC2s than in WT ILC2s after 24 and 48 hr of
culture (Figure 2G). Taken together, these data suggest that
although production of IL-13 is directly affected by a lack of
ICOS, IL-5 production in Icos/ mice is also ultimately lower
because of the lower number of viable ILC2s in these mice.
Because we found that ILC2 survival was reduced in the
absence of ICOS, we next investigated whether the expression
of the receptors that might mediate the survival of ILC2s are
altered in Icos/ mice. We evaluated the expression of CD25,
CD127, ST2, and CD117 in ILC2s in Icos/ and WT mice in
the steady state (mice were treated with PBS) and after stimula-
tion with IL-33. To confirm the phenotype of Icos/ mice, we
also evaluated the level of ICOS in both strains. Although there
was no significant difference between the expression of
CD127, ST2, and CD117, the expression of CD25 was increased
in Icos/ mice, suggesting an altered sensitivity to IL-2 in the
absence of ICOS (Figure S2B).
A Lack of ICOS Impairs STAT5 Activation
Becauseweobserved that the amount of IL-2Rawas increased in
ILC2s from Icos/mice,wecompared the sensitivities ofWTand
Icos/ ILC2s to IL-2 by testing the phosphorylation of STAT5 in
response to IL-2 stimulation in ILC2s. Icos/ and WT mice
were challenged intranasally by either rm-IL-33 (0.5 mg /mouse)
or PBS. After 24 hr, single lung cells were stimulated with recom-
binantmurine IL2 (100ng/ml) for 30min, then ILC2swereanalyzed
for the expression of phosphoSTAT5. The amounts of phospho-
STAT5 in ILC2s from PBS-treated WT and Icos/ mice were
similar, and IL-33-treated Icos/ ILC2s showasignificantly lower
amountof phosphoSTAT5 thandoWTmice (Figure 2H). These re-
sults suggest a reduced sensitivity to IL-2 signaling despite higher
expression of IL-2Ra in Icos/ ILC2s.
Next we evaluated the expression of the transcription factor
GATA binding protein-3 (GATA-3), which has been associated
with the development and maintenance of ILC2s (Hoyler et al.,
2012; Klein Wolterink et al., 2013). We administered either rm-
IL-33 (0.5 mg/mouse) or PBS intranasally to Icos/ or WT mice
and analyzed the expression of GATA-3 in ILC2s after 24 hr.
There was no difference in the expression of GATA-3 in ILC2s
of Icos/ andWTmice after either IL-33 or PBS treatments (Fig-
ure 2I). These results suggest that the GATA-3 pathway in ILC2s
is not affected by the lack of ICOS.
To further investigate the mechanism of reduced cell survival
and impaired cytokine production in Icos/ ILC2s, we analyzed
the gene expression profile of naive and IL-33-stimulated WT
and Icos/ ILC2s by using Nanostring technology as described
in the Experimental Procedures. Nanostring nCounter allows
direct measurement of the abundance of transcripts (Schmitt
et al., 2014). The evaluated genes are categorized and shown
in three panels. (1) genes that are mainly involved in the
IL-2/IL-7 signaling pathway, (2) genes that are involved in the
IL-33/IL-25 signaling pathway, and (3) transcription factors (Fig-
ure 2J). As demonstrated in the panel for the IL-2/IL-7 signaling
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A Figure 2. Lack of ICOS Increases Cell
Death and Impairs Cytokine Production in
ILC2s
BALB/cBYJ and Icos/ mice received i.n. IL-33
or PBS, and after 24 hr lungs were either imme-
diately analyzed for apoptosis, cell death, and
proliferation or cultured in the presence of IL-33
(20 ng/ml) and Brefeldin A for 6 hr followed by
intracellular cytokine analysis. ILC2s were gated
on the basis of being lineage, CD45+, CD90.2+,
ST2+, and CD25+.
(A) Dead-cell-discrimination dye (DCD) and an-
nexin V staining of ILC2s of WT and Icos/mice.
Early apoptotic (EA) (Annexin V+, DCD), late
apoptotic (LA) (annexin V+, DCDint), and dead
cells (DCDhi) are shown. Numbers show the per-
centage of the gate.
(B) The frequency of EA, LA, and dead cells within
ILC2s.
(C) Histogram (left panel) and median fluores-
cence intensity (right panel) of BCL-2 in ILC2s.
(D) Histogram (left panel) and median fluores-
cence intensity (right panel) of Ki-67 in ILC2s as
an indication of proliferation.
(E) Production of IL-5, IL-13, IL-4, and IL-17A in
ILC2s of WT and Icos/ mice.
(F) Bar graphs showing the percent of cytokine-
producing cells within the ILC2 gate.
(G) ILC2swere purified by FACS and cultured (104
cells/100 ml) in the presence of rm-IL-33 (20 ng/
ml), rm-IL-2 (10 ng/ml), and rm-IL-7 (10 ng/ml) for
24 and 48 hr. The concentrations of IL-5 and IL-13
produced by purified lung ILC2s as measured by
ELISA are shown.
(H) Histogram (left panel) and median fluores-
cence intensity (right panel) of phosphorylated
STAT5in ILC2s.
(I) Histogram (left panel) andmedian fluorescence
intensity (right panel) of GATA3 expression in
ILC2s.
(J) Heat-plot demonstration of modulation of the
depicted genes in FACS-purified Icos/ ILC2s
compared to WT ILC2s in steady state and after
three i.n. IL-33 administrations quantified by
Nanostring nCounter technology. Data are
ranged 1 to +1 for the most reduced and most
increased gene expression, respectively.
In panels (A) through (I), data are representative of
at least three independent experiments and are
shown as means ± SEM (n = 5, **p < 0.01, *p <
0.05).
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pathway, the expression of STAT5b, STAT5a, and NFATc2 was
reduced in naive Icos/ ILC2s, whereas this reduction was less
pronounced after IL-33 stimulation. Given the implication of
STAT5 and NFATc2 for cell survival and our observation that
phosphorylation of STAT5 is reduced in the absence of ICOS,
this finding might explain the reduced number and higher rate
of death of Icos/ ILC2s in the steady state. The expression
of IL2ra seems to be reduced in steady state and after IL-33 stim-
ulation in Icos/ ILC2s, whereas we found increased expression
by flow cytometry. These seemingly conflicting findings suggest
a possible difference in the translation rate of IL-2Ra in Icos/
versus WT ILC2s because protein amount is measured by flow
cytometry, whereas Nanostring analyzes gene expression. The
expression of IL-2Rb seems to be increased in the steady state
in Icos/ ILC2s. The most notable differences in IL-33/IL-25
signaling were increased IL-33R in the steady state, decreased
IL-17RB-receptor gene expression, and a modest decrease in
JAK2 signaling in naive and IL-33-stimulated states (Figure 2J,
middle panel). In the transcription-factor panel, gene expression
of Gata3 seemed to be increased in Icos/ ILC2, whereas Id2
expression was decreased in steady state. However, we did
not find a significant difference in GATA-3 protein amounts by
flow cytometry. Thus, a lack of ICOS mainly affects the IL-2
signaling pathway.
Adoptively Transferred Icos–/– ILC2s Fail to Induce AHR
in Alymphatic Hosts
To confirm our findings and to eliminate the effect of bystander
cells, including T cells subsets that can express IL-33 receptor
(Kim et al., 2012; Lo¨hning et al., 1998), we first transferred puri-
fied ILC2s (1.5 3 104 cells/mouse) from Icos/ or WT mice
into Rag2/Il2rg/ mice and then administered either IL-33
(0.5 mg/mouse) or PBS intranasally on 3 consecutive days and
evaluated lung function and inflammation a day after the last
i.n. treatment (Figure S3A). I.n. IL-33 administration leads to
significantly increased lung resistance and inflammation and
decreased lung compliance in the recipients of WT ILC2s but
not in the recipients of Icos/ ILC2s (Figures S3B–S3D). Lung
resistance and dynamic compliance are significantly lower in
IL-33-treated recipients of Icos/ ILC2s than in recipients of
WT ILC2s (Figures S3B–S3D). The number of ILC2s in the lungs
of recipients of Icos/ ILC2s was significantly lower than that in
recipients of WT ILC2s (Figure S3E).
To exclude the effects of the host and further address the role
of bystander T cells in the observed phenotype of Icos/ ILC2s,
we transferred either purified WT ILC2s (WT ILC2 group, 1.5 3
104 cells/mouse) combined with Icos/ CD4+ T cells (3 3 106
cells/mouse) or Icos/ ILC2s (Icos/ group, 1.5 3 104 cells/
mouse) combined with WT CD4+ T cells (3 3 106 cells/mouse)
into alymphoid mice. Similar to the aforementioned experiment,
upon adoptive cell transfer mice received three i.n. administra-
tions of IL-33 on consecutive days and were dissected one
day after the last i.n. treatment (Figure 3A). As expected, IL-33
treatment led to a significant increase in lung resistance, inflam-
mation, and eosinophil count in the BAL of theWT ILC2-recipient
group but not in the Icos/ ILC2-recipient group (Figures 3B,
3D, and 3E). Lung dynamic compliance shows a significant
decline in the basal level after IL-33 administration but no further
decrease in theWT ILC2 recipient group (Figure 3C). The number542 Immunity 42, 538–551, March 17, 2015 ª2015 Elsevier Inc.of ILC2s in the lungs and all other measured parameters were
significantly lower in Icos/ ILC2 recipients than in WT ILC2 re-
cipients after i.n. IL-33 administration (Figure 3B and 3F). Taken
together, these data indicate that expression of ICOS by ILC2s is
required for the function and survival of ILC2s in vivo.
Blocking ICOS in Rag2–/– Mice Hinders IL-33-Induced
AHR and Lung Inflammation
Next we examinedwhether blocking ICOS-ICOS-L binding leads
to the same results we observed in Icos/ mice. We examined
the effects of anti-ICOS blocking antibody on IL-33-induced
AHR and lung inflammation in Rag2/ mice that lacked mature
B and T cells. Rag2/ mice received either anti-ICOS (500 mg/
mouse, clone 7E.17G9) or Rat IgG2b (isotype-matched control)
intraperitoneally on day 1, and each group also received either
IL-33 (0.5 mg /mouse) or PBS intranasally on days 1–3. Measure-
ment of lung function and sample acquisition followed on day 4
(Figure 4A). Lung-function data show that i.n. IL-33 adminis-
tration increases lung resistance (Figure 4B) and decreases
dynamic compliance (Figure 4C) in WT mice. In contrast, lung
resistance in IL-33-treated mice that received anti-ICOS was
significantly lower, and dynamic compliance higher, than in IL-
33-treated isotype-control-receiving mice (Figures 4B and 4C).
Lung histology showed that IL-33 treatment led to a thickening
of the epithelium and increased inflammatory cells in isotype-
control but not anti-ICOS-treated mice (Figure 4D). Similarly,
the number of eosinophils in the BAL was significantly higher in
IL-33-treated than in PBS-treated mice, but it was significantly
lower in anti-ICOS-treated than in isotype-treated mice (Fig-
ure 4E). Anti-ICOS antibody significantly reduced the number
and frequency of ILCs over what was found in mice receiving
the isotype control (Figures 4F and 4G). We also analyzed the
cytokine production in ILC2s by intracellular staining and found
that anti-ICOS administration significantly reduced the produc-
tion of IL-13 but not IL-5 in comparison to findings for mice
receiving the isotype control (Figures 4H and 4I). These results
indicate that binding of ICOS to ICOS-L is required for efficient
function in ILC2s.
ICOS Is Required for the Induction of Allergen-Induced
AHR and Lung Inflammation
We next investigated whether ICOS on ILC2s is required for the
induction of AHR and lung inflammation induced by a clinically
relevant allergen. Rag2/ mice received either anti-ICOS or
Rat IgG2b intraperitoneally on day 1 and extract of Alternaria
alternata (100 mg/mouse) intranasally on days 1–4, followed by
measurement of lung function and sample withdrawal on day 5
(Figure 5A). As shown in Figures 5B and 5C, administration of Al-
ternaria induced AHR, as evidenced by increased lung resis-
tance and decreased dynamic compliance, in isotype-treated
but not anti-ICOS-treatedmice (p < 0.05 at dose 40). Lung histol-
ogy showed an increased thickening of the epithelium and an
increased number of inflammatory cells in Alternaria-treated,
isotype-receiving mice but not in Alternaria-treated, anti-ICOS-
receiving mice (Figure 5D). The number of eosinophils was
increased in the BAL of Alternaria-treated WT mice, but it was
lower in anti-ICOS-treated than in isotype-treated mice (Fig-
ure 5E). In addition, the total number of ILC2s was significantly
lower in anti-ICOS-receiving than in isotype-receiving mice
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Figure 3. Icos–/– ILC2s Fail to Induce AHR
and Lung Inflammation
(A) ILC2s and splenic CD4+ T cells were purified
from BALB/cBYJ and Icos/ mice via FACS. WT
ILC2s (1.5 3 104 cells/mouse) combined with
splenic Icos/ CD4+ T cells (3 3 106 cells/mouse)
or Icos/ ILC2s combined with WT CD4+ T cells
were injected into NSG mice intravenously, and
three intranasal challenges with rm-IL-33 or PBS
on 3 consecutive days followed. 1 day after the last
challenge, lung function was measured and sam-
ples were collected.
(B and C) Lung resistance (B) and dynamic
compliance (C).
(D) Lung histology after PBS or IL-33 treatment.
(E) Total eosinophils in the BAL in PBS- or IL-33-
treated mice.
(F) Total ILC2s in the lungs after PBS or IL-33
treatment.
Data are representative of two independent
experiments and are shown as means ± SEM (n =
3–5, *p < 0.05).(Figure 5F). These results suggest that ICOS plays an important
role in the function of ILC2 in response to clinically relevant
allergens.
ILC2s Express Functional ICOS-L
Next, we examined whether ILC2s express ICOS-L. We admin-
istered i.n. rm-IL33 (0.5 mg/mouse) or PBS to WT and Icos/
mice and analyzed ILC2s for the expression of ICOS-L by flow
cytometry after 24 hr. Whereas WT ILC2s expressed low
amounts of ICOS-L, Icos/ ILC2s expressed high amounts of
ICOS-L in both PBS- and IL-33-treated mice (Figures 6A and
6B). Because it has been shown that ICOS-L is downregulated
in APCs upon binding to ICOS (Watanabe et al., 2008), we hy-
pothesized that ICOS-L is downregulated in WT ILC2s uponImmunity 42, 538–55binding to ICOS. To test our hypothesis,
we cultured ILC2s from PBS- and IL-33-
treated mice in the presence of anti-
ICOS (10 mg/ml) or Rat IgG2b (10 mg/ml)
for 24 hr. We found that although a low
level of ICOS-L expression could be de-
tected in cultured ILC2s in the presence
of isotype control, the expression of
ICOS-L was significantly increased in
cultured ILC2s in the presence of anti-
ICOS antibody (Figures 6C and 6D).
To confirm the functionality of ICOS-L
in ILC2s, we evaluated phosphoSTAT5
and production of IL-13 by purified
cultured ILC2s in the presence of plate-
bound mouse ICOS-L-IgG (5 mg/ml)
fusion protein or plate-bound human IgG
(isotype control). The culture media was
supplemented with rm-IL2 (100 ng/ml),
rm-IL-33 (100 ng/ml), and IL-7 (20 ng/
ml). PhosphoSTAT5 was increased in
the presence of ICOS-L-IgG as compared
to isotype control (Figure 6E). Moreover,purified ILC2s produce a significantly higher amount of IL-13 in
the presence of ICOS-L-IgG than in the presence of isotype con-
trol, whereas IL-13 production is dramatically reduced in the
presence of anti-ICOS-L mAb (Figure 6F).
To address whether the ICOS:ICOS-L interaction is cis or
trans, we co-cultured Icos/ ILC2s with WT ILC2s in the pres-
ence of anti-ICOS blocking or isotype-matched antibodies.
Because ICOS-L is downregulated upon interaction with ICOS,
we used ICOS-L expression as an indication of ICOS:ICOS-L
binding. We found that ICOS-L expression in the presence of
anti-ICOS blocking antibody is lower than that of the isotype-
matched control, suggesting that trans interaction occurs. More-
over, the readily lower level of ICOS-L expression in WT ILC2s
than in Icos/ ILC2s suggests cis transaction aswell (Figure S4).1, March 17, 2015 ª2015 Elsevier Inc. 543
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Figure 4. Blocking ICOS Inhibits AHR and Lung Inflammation in RAG2-Deficient Mice
(A)Rag2/mice received 500 mg/mouse anti-mouse ICOS-blocking antibody or rat IgG2b (isotype control) on day 1 and received rm-IL-33 or PBS intranasally on
days 1–3. Measurement of lung function and analyses of BAL and lung histology followed on day 4.
(B and C) Lung resistance (B) and dynamic compliance (C).
(D) Lung histology.
(E) Total numbers of eosinophils in the BAL.
(F) Total number and (G) frequency of ILC2s.
(H) Dot plot of intracellular cytokine production by lung ILC2s after 4 hr of culture in the presence of Brefeldin A.
(I) Median fluorescence intensity of intracellular IL-5 and IL-13 in lung ILC2s.
Data are representative of at least three independent experiments and are presented asmeans ± SEM (n = 5; *p < 0.05 for anti-ICOS + IL33 compared to isotype +
IL33; ###p < 0.005 for isotype + IL-33 compared to isotype + PBS; ##p < 0.01 for isotype + IL-33 compared to isotype + PBS).
544 Immunity 42, 538–551, March 17, 2015 ª2015 Elsevier Inc.
Fr
eq
ue
nc
y
of
IL
C
2
in
lu
ng
( %
of
to
ta
ll
un
g
ce
lls
)
x 1
04
to
ta
l I
L C
2
in
l u
ng
+ +Alt. Alt. Alt.+
*
*
*
*
Isotype
Anti-ICOS
Isotype
Anti-ICOS
0
1
2
3
4
x1
0
5
eo
si
no
ph
ils
in
BA
L
cD
yn
(x
10
-2
.m
l.c
m
H
2O
-1
)
0
1
2
3
0
5
10
15
20
*
*
*
*
*
Anti-ICOS
A B
E
C
F GD
Day
i.n. Alternaria (100 μg)
or PBS
i.p. Anti ICOS
(500 μg)
1 2 3 4 5
Lung function
Lung and BAL analysis
Methacholine (mg-1.ml)
R
es
is
ta
nc
e
(c
m
H
2O
.m
l-
1 .
S
- 1 )
Isotype
PB
S
A
lte
rn
ar
ia
Methacholine (mg-1.ml)
0 5 10 20 40 0 5 10 20 40
0
2
4
6
8
10 Isotype-PBS
Isotype-Alternaria
Anit-ICOS-PBS
Anti-ICOS-Alternaria
0
0.5
1.0
1.5
2.0
2.5
**
*
Figure 5. Blocking ICOS Inhibits Alternaria-Induced AHR and Lung Inflammation
(A)Rag2/mice received intraperitoneal injection of anti-mouse ICOS-blocking antibody or rat IgG2b on day 1 and received extract ofAlternaria alternata or PBS
intranasally on days 1 4, followed by measurement of lung function and analysis of BAL and lung histology on day 5.
(B and C) Lung resistance (B) and dynamic compliance (C) in response to increasing doses of methacholine.
(D) Lung histology.
(E) Total numbers of eosinophils in the BAL.
(F) Total number of lung ILC2s.
Data are representative of at least three independent experiments and are presented as means ± SEM (n = 4, **p < 0.01, *p < 0.05).We next addressed whether ICOS:ICOS-L binding leads to
increased BCL2 expression and ILC2 survival by testing the
stimulatory effects of exogenous plate-bound ICOS-L-IgG on
ILC2s in vitro. As shown in Figure 6A, ICOS-L-IgG stimulation
leads to increased expression of BCL2 and enhanced survival
of WT ILC2s. These data show that ILC2s express ICOS-L in
addition ICOS and that expression of ICOS-L plays a functional
role in ILC2 cytokine production and survival.
Human Peripheral ILC2s Express Functional ICOS and
ICOS-L
We next investigated whether human ILC2s express ICOS and
ICOS-L and whether ICOS and ICOS-L play a crucial role in
the function of human ILC2s. Peripheral blood from healthy do-
nors was collected and gated for ILC2s on the basis of the lack
of expression of human lineage markers (CD3, CD14, CD16,
CD19, CD20, CD56, CD235a, CD1a, andCD123) and expression
of CD45, CRTH2, CD127, and CD161 (Figure 7A), then analyzed
for the expression of ICOS and ICOS-L (Figures 7B and 7C, left
panels). Alternatively, human peripheral bloodmononuclear cells
(PBMCs) were cultured in the presence of both recombinant hu-man IL-2 (rh-IL-2; 20 ng/ml) and rh-IL-7 (20 ng/ml) in the pres-
ence or absence of rh-IL-33 (20 ng/ml) for 24 hr and expression
of ICOS and ICOS-L was evaluated by flow cytometry (Figures
7B and 7C, right panels). We found that ICOS is expressed by hu-
man peripheral ILC2s at steady state and that its expression is
increased upon in vitro culture with IL-2 and IL-7, whereas
IL-33 stimulation does not affect the expression of ICOS by hu-
man ILC2s (Figure 7B). We found, similar to findings in mouse
ILC2s human peripheral ILC2s express ICOS-L at a low basal
level that is modestly increased after in vitro stimulation by IL-2
and IL-7, whereas it is modestly decreased by IL-33 (Figure 7C).
To evaluate the functional requirement of ICOS-ICOS-L bind-
ing for cytokine production by human ILC2s, we purified ILC2s
from PBMCs and cultured them in the presence of rh-IL-2
(20 ng/ml), rh-IL-7 (20 ng/ml), and rh-IL-33 (20 ng/ml) in the
presence of blocking anti-human-ICOS-L antibody (10 mg/ml,
clone 9F.8A4) or isotype control for 72 hr, then measured
IL-13 and IL-5 production in the supernatant. The results
showed that blocking the ICOS-ICOS-L interaction significantly
reduces production of IL-13 and IL-5 by human cultured ILC2s
(Figure 7D).Immunity 42, 538–551, March 17, 2015 ª2015 Elsevier Inc. 545
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Figure 6. Murine ILC2s Express ICOS-L
(A) Histogram of expression of ICOS-L by ILC2s in
BALB/cBYJ (thin line) and in Icos/ (thick line)
mice 24 hr after i.n. IL-33 or PBS administration.
The level of isotype-matched stain control is shown
as a gray-filled histogram.
(B)Median fluorescence intensity of ICOS-L inwild-
type and Icos/mice in intranasally IL-33- or PBS-
treated mice.
(C) Histogram of expression of ICOS-L by lung
ILC2s in BALB/cBYJ mice 24 hr after administra-
tion of blocking anti-ICOS (thick line) or rat IgG2a
(thin line) in PBS- or IL-33-treated mice.
(D) Median fluorescence intensity of ICOS-L in lung
ILC2s of BALB/cBYJ mice treated with blocking
anti-ICOS (black bars) or rat IgG2a isotype control
(white bars) antibody after PBS or IL-33 adminis-
tration.
(E) Histogram of the amounts of phosphorylated
STAT5 24 hr after in vitro culture of purified ILC2s in
the presence of plate-bound ICOS-L IgG or, as an
isotype control, human IgG.
(F) Production of IL-13 by purified ILC2s (104 cells/
100 ml) in the presence of plate-bound ICOS-L IgG
or human-IgG after 24 hr culture as measured by
ELISA. For the culture media, RPMI was supple-
mented with 10% fetal bovine serum (FBS) and rm-
IL-2 (20 ng/ml), rm-IL-7 (20 ng/ml), and rm-IL-33
(20 ng/ml).
(G) Purified WT ILC2s were cultured in the absence
of stimuli. After 24 hr, cells were transferred to new
plates with plate-bound ICOS-L IgG or human IgG
and cultured with RPMI supplemented with 10%
FBS, rm-IL-2 (20 ng/ml), rm-IL-7 (20 ng/ml), and
rm-IL-33 (20 ng/ml). Expression of BCL-2 (left
panel) and viability (right panel) as measured by
flow cytometry are shown.
Data are representative of at least three indepen-
dent experiments and are presented as means ±
SEM (n = 3–4, **p < 0.01, *p < 0.05).To further confirm that human ILC2s have a functional require-
ment for the ICOS-ICOS-L interaction, wepurified ILC2s formhu-
man PBMCs and, after 3 days of in vitro culture in the presence of
rh-IL-2 (20 ng/ml) and rh-IL-7 (20 ng/ml), adoptively transferred
ILC2s through the tail vain to Rag2/ Il2rg/ mice, which
lack T, B, and NK cells and ILCs. Then mice received either
anti-human-ICOS-L plus anti-mouse-ICOS-L (clones 9F.8A4
and 16F.7E5, 500 mg/mouse each) or isotype control on day 1
and either i.n. rh-IL-33 (1 mg/mouse) or i.n. PBS on days 1–3 (Fig-
ure 7E).Onday 4,wemeasured lung function asdescribed above
and assessed the BAL. IL-33 treatment induced AHR inmice that
received isotype control, whereas IL-33 failed to induce AHR in
mice that received anti-ICOS-L antibodies (Figure 7F). IL-33
treatment significantly increased the number and frequency of
eosinophils in the BAL in isotype-control-treated but not anti-546 Immunity 42, 538–551, March 17, 2015 ª2015 Elsevier Inc.ICOS-L-treated mice (Figure 7G). The
number and frequency of eosinophils
were significantly lower in mice that
received anti-ICOS-L than in recipients of
isotype control (Figure 7G). Taken
together, these results indicate that hu-man peripheral ILC2s express both ICOS and ICOS-L and that
the ICOS:ICOS-L interaction plays a crucial role for the function
of human ILC2s.
DISCUSSION
In this study we demonstrate that ICOS is required for ILC2-
mediated induction of airway hyperreactivity and inflammation
in murine models and human ILC2-reconstituted mice. We
showed that mouse and human ILC2s expressed both ICOS
and ICOS-L and that the ICOS:ICOS-L interaction is required
for efficient ILC2 function and provides a survival signal for
ILC2. We further demonstrated that blocking the ICOS:ICOS-L
interaction impairs STAT5 signaling and IL-13 production in
ILC2s.
95.3
A
C
B
D E
F G H
-IL33Fresh
24H cultured
+IL33
Li
ne
ag
e
CRTH2
SS
C
CD45
C
D
12
7
CD161
*
C
ou
nt
ICOS
C
ou
nt
ICOS Ligand
IL-33 +IL-33 +
+
Rag2-/- Il2rg-/-
ILC2
Isotype Anti-ICOS-L
x1
03
 e
os
in
op
hi
ls
 in
 B
AL
x1
03
 IL
C
2s
 in
 L
un
g
0 5 10 20 40
0
4
8
12
Methacholine (mg-1.ml)
R
es
is
ta
nc
e 
(c
m
H
2O
.m
l-
1 .
S
-1 )
0.065
Anti-ICOSL +Anti-ICOSL
0
1
2
3
4
IL
-1
3 
(x
10
2  
pg
/m
l)
IL
-5
 (x
10
 p
g/
m
l)
0
5
10
15 *
*
i.n. IL33 (0.5 μg),
or PBS
Day
i.p. Anti ICOS-L
(500 μg)
1 2 3 4
Lung function
Lung and BAL analysis
Isotype-PBS
Isotype-IL-33
Anit-ICOSL-PBS
Anti-ICOSL-IL-33
69.5 95.3 95
-IL33Fresh
24H cultured
+IL33
98.2
Gated on Single cells
0
1
2
3
4
5
28.8 34.5 24.3
* * * *
0
2
4
6
8
Figure 7. HumanPeripheral ILC2s Express ICOS
and ICOS-L, and Blocking Their Interaction Re-
duces Cytokine Production by ILC2s
Human peripheral-blood mononuclear cells were iso-
lated via Ficoll gradient isolation and cultured in the
presence or absence of recombinant human IL-33
(20 ng/ml), IL-2 (10 ng/ml), and IL-7 (20 ng/ml) for 24 hr.
(A) Human peripheral ILC2s were gated on single cells,
CD45+ CRTH2+ lineage, CD127+, and CD161+ cells
(B and C) Expression of ICOS (B) and ICOS-L (C) was
measured in freshly isolated human peripheral ILC2s
(left panels). Moreover, purified ILC2s were cultured in
the absence or presence of rh-IL-33 (20 ng/ml) for 24 hr,
after which expression of ICOS and ICOS-L was
measured (middle and right panels). Stain isotype
control is shown in a gray-filled histogram.
(D) Human ILC2s were purified from PBMCs via FACS
and cultured (104 cells/ml) in the presence of rh-IL-33
(20 ng/ml), IL-2 (10 ng/ml), and IL-7 (20 ng/ml) for 24 hr.
Data are representative of four individual donors.
(E) Human peripheral ILC2s were purified via FACS and
cultured with rh-IL2 (20 ng/ml) and rh-IL-7 (20 ng/ml) for
48 hr, then adoptively transferred into two groups of
Rag2/ Il2rg/ mice that received either anti-human
and anti-mouse ICOS-L (500 mg/mouse) or isotype
control (500 mg/mouse) on day 1. Both groups received
either rh-IL-33 (0.5 mg/mouse) or PBS intranasally on
days 1–3, followed by dissection on day 4.
(F) Lung resistance.
(G) Total numbers of eosinophils in the BAL.
(H) Total numbers of human ILC2s in the lungs of hu-
manizedmice (n = 3–4). Data are representative of three
independent experiments (*p < 0.05, n = 3–4).
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In the absence of ICOS, both IL-33 and Alternaria induce less
AHR and lung inflammation. We used the IL-33-based model to
test the functional requirement for ICOS in cytokine production
and survival of ILC2s because IL-33 and IL-25 had been previ-
ously shown to induce ILC2-mediated AHR and lung inflamma-
tion in RAG-deficient mice; IL-33 has been found to be more
potent than IL-25 (Barlow et al., 2012; Barlow et al., 2013; Chang
et al., 2011; Fort et al., 2001). We used Alternaria because it is a
common fungus in the environment and an allergen in humans
and has been shown to cause allergic inflammation in mice inde-
pendently of adaptive immunity (Doherty et al., 2013; Kim et al.,
2014). Our results suggest that in addition to AHR, ILC2-medi-
ated induction of lung inflammation and eosinophilia depend
on ICOS. In line with our findings, it has been shown that ICOS
is required for T cell-mediated lung inflammatory responses
(Gonzalo et al., 2001).
We observed reduced numbers of ILC2s in Icos/ compared
to WTmice, which suggests that ICOS plays an important role in
the survival and/or proliferation of ILC2s. By analyzing ILC2
apoptosis and death, we found that the frequency of dead cells
was increased in the absence of ICOS, whereas the frequency of
early and late apoptotic ILC2s was comparable. Similarly, we
found that the expression of anti-apoptotic factor BCL-2 was
significantly lower in Icos/ than in WT ILC2s. Evaluation of
ILC2 proliferation by measurement of the expression of Ki-67,
a protein associated with cell proliferation, revealed that the
rate of proliferation of ILC2s is similar in Icos/ and WT mice.
These findings suggest that although ICOS provides a survival
signal for ILC2s, it is not essential for proliferation of ILC2s. In
agreement with our findings in ILC2s, it has been shown that
ICOS substantially contributes to survival of effector T cells
upon antigen exposure; however, Burmeister, et al., have also
observed a role of ICOS in T cell expansion (Burmeister et al.,
2008).
ICOS substantially contributes to cytokine production by
ILC2s. Using intracellular staining and gating on the live cells,
we found that upon stimulation with IL-33, production of IL-13
is significantly reduced in the absence of ICOS, and the produc-
tion of IL-13 and IL-5 in the supernatant is reduced upon in vitro
stimulation in the absence of ICOS. Similarly, it has been shown
that ICOS plays an important role in the production of IL-13 and
IL-4 in T cells (Dong et al., 2001). These data indicate that IL-13
production is directly affected by a lack of ICOS; however,
because of the higher rate of ILC2 death, the sum production
of IL-5 is also reduced in the absence of ICOS. This is in agree-
ment with the finding that Icos/mice display reduced amounts
of AHR andBAL eosinophilia, which reflect the in vivo amounts of
IL-13 and IL-5, respectively.
We show that mouse and human ILC2s express functional
ICOS-L and that the ICOS:ICOS-L interaction is required for sur-
vival and cytokine production of ILC2s. Expression of both ICOS
and ICOS-L by ILC2s explains the reduced cytokine production
after blocking of the ICOS:ICOS-L interaction in purified in vitro
cultures of ILC2s.We found that blocking the ICOS:ICOS-L inter-
action increases the expression of ICOS-L in WT mice and that
Icos/ ILC2s readily express high levels of ICOS-L. These find-
ings suggest that ICOS-L is downregulated upon binding to
ICOS. In agreement with our observations, it has previously
been shown that the ICOS:ICOS-L interaction leads to downre-548 Immunity 42, 538–551, March 17, 2015 ª2015 Elsevier Inc.gulation of ICOS-L in B cells (Watanabe et al., 2008). To our
knowledge, this is the first report of expression of ICOS and
ICOS-L by the same type of cells. Because it has been reported
that ILC2s (previously reported as nuocytes) might express
MHC-II (Neill et al., 2010) and because we observed that they ex-
press ICOS-L, determining whether these cells can engage in
antigen-presentation activities will require further investigation.
Several reports have shown that GATA-3 is expressed by
ILC2s and that it plays a crucial role in the development, main-
tenance, and function of ILC2s (Hoyler et al., 2013; Hoyler et al.,
2012; Klein Wolterink et al., 2013; Mjo¨sberg et al., 2012), and
IL-13 production by ILC2s has been associated with a high
level of expression of GATA-3 (Liang et al., 2012). However,
when we compared the expression of GATA-3 in WT ILC2s
with that in Icos/ ILC2s at steady state and after IL-33
stimulation, we found comparable levels of GATA-3, suggest-
ing that impairment of IL-13 production by Icos/ ILC2s is
caused by a mechanism other than the reduction of GATA-3
expression.
We found that STAT-5 signaling was impaired in Icos/
ILC2s. The expression of phospho-STAT5 in Icos/ ILC2s
was substantially lower than that in WT ILC2s. This finding sug-
gests that a lack of ICOS leads to alteration in IL-2 and IL-7
signaling. Interestingly, STAT5 is required not only for IL-2-
mediated cell survival and Th2 differentiation but also for effi-
cient production of IL-13 in T cells and mast cells (Antov
et al., 2003; Junttila et al., 2013; Moriggl et al., 1999; Zhu
et al., 2003). We further investigated ICOS signaling by using
plate-bound ICOS-L-Fc, which consists of mouse ICOS-L fused
with the Fc part of human IgG, and found that ICOS-L-Fc in-
creases the amount of phospho-STAT5 and leads to higher
IL-13 production. Taken together, our data suggest that ICOS
plays an important role in ILC2 cell survival and cytokine pro-
duction through the IL-2 and STAT-5 signaling pathway, which
might be unique to ILC2s.
In addition, we introduce a humanized mouse model in
which human peripheral ILC2s are adoptively transferred to
Rag2/Il2rg/ mice and i.n. administration of hu-IL-33
causes AHR and inflammation. Human IL-5 has been shown
to activate murine eosinophils, emphasizing the feasibility of
using humanized mice in eosinophilic inflammatory studies
(Ingley et al., 1991; Tavernier et al., 1995). This mouse model
provides a unique platform for studying the contribution of
ILC2s to human asthma and evaluating the efficacy of potential
therapeutic targets in preclinical studies. Using this model, we
show that the ICOS:ICOS-L interaction is required for efficient
function of human ILC2s in vivo. These findings underscore the
importance of the ICOS signaling pathway for efficient function
of human ILC2s and demonstrate that our findings in mouse
ILC2s are of high importance for and translatable to clinical
studies.
In conclusion, our study demonstrates that human and mouse
ILC2s express ICOS and ICOS-L and that the ICOS:ICOS-L
interaction provides a survival signal for ILC2s and is required
for efficient cytokine production by ILC2s. We show that the
STAT5 signaling pathway is impaired in Icos/ ILC2s and
that it is enhanced through ICOS signaling, leading to higher
cytokine production. This might provide an explanation for the
lower rate of survival and cytokine production in the absence
of ICOS or after blockade of ICOS:ICOS-L signaling. We in-
troduce a humanized mouse model in which human ILC2s
drive AHR in mice, and we use this system to show that the
ICOS:ICOS-L interaction is required for optimal function of hu-
man ILC2s in vivo. because ILC2s are the only cells that express
both ICOS and ICOS-L, our findings set the stage for designing
new therapeutic approaches that target ILC2s to treat asthma,
for instance by using dual specific antibodies that recognize
ICOS and ICOS-L.
EXPERIMENTAL PROCEDURES
Mice and In Vivo Experiments
ICOS-deficient mice (C.129S4-Icostm1Shr/J) were obtained from Arlene Sharpe
(HarvardMedical School, Boston, Massachusetts). RAG2-deficient (C.B6(Cg)-
Rag2tm1.1Cgn/J), RAG2-, IL-2Rg-deficient (C;129S4-Rag2tm1.1Flv Il2rgtm1.1Flv/J)
breeder pairs and BALB/cBYJ experimental mice were purchased from the
Jackson Laboratory (Bar Harbor, Maine). NSG experimental mice were pur-
chased from the Jackson Laboratory. RAG2-deficient mice, RAG2-, GC-defi-
cient mice, and ICOS-deficient mice were bred in our animal facility at the
University of Southern California. 5- to 8-week-old age-matched female
mice were used in the studies. In vivo and in vitro ILC2 stimulation are
described in detail in the Supplemental Experimental Procedures.
Analysis of Intracellular Factors by Flow Cytometry
Cytokine production was assessed with BD Cytofix/Cytoperm containing BD
Golgi-Plug (BD Biosciences) according to the manufacturer’s instructions,
and staining with anti-IL-5, anti-IL-13, anti-IL4, and anti-IL-17a antibodies
was performed as mentioned above.
We assessed GATA-3 and BCL-2 expression by fixing and permeabilizing
cells with a fixation and permeabilization buffer kit (eBioscience) according
to the manufacturer’s instructions and then stained cells with anti-GATA-3
and anti-BCL-2 antibodies as mentioned above.
The expression of phosphorylated STAT5 was measured after stimulation
of cells with rm-IL-2 (100 ng/ml) in the presence or absence of rm-IL-33
(100 ng/ml) for 30 min. Surface staining and then fixation and permeabilization
with BD CytofixFixation Buffer and BD Phosflow Perm Buffer III followed ac-
cording to the manufacturer’s instructions, and staining was performed with
anti-mouse pSTAT5 as mentioned above.
Humanized Mice and Purification of HumanILC2
For human peripheral ILC2, peripheral blood mononuclear cells (PBMCs)
were first isolated from human fresh blood as described in detail in the Sup-
plemental Experimental Procedures. Purified human ILC2s were cultured
with rh-IL2 (20 ng/ml) and rh-IL-7 (20 ng/ml) for 3 days, then adoptively
transferred to Rag2/Il2rg/ mice (2 3 104 cells/mouse). i.n. administra-
tion of recombinant human IL-33 (0.5 mg/mouse) or PBS on days 1–3 fol-
lowed. On day 1, mice received either anti-human (clone: 9F.8A4, 500 mg/
mouse) and anti-mouse ICOS-L (clone: 16F.7E5, 500 mg/mouse) or iso-
type-matched control (500 mg/mouse). On day 4, lung function was
measured, and BAL was performed and analyzed. Anti-ICOS-L antibodies
were generated by Dr. Gordon Freeman as described elsewhere (Akbari
et al., 2002).
Cytokine Measurement in the Supernatant
Human IL-5 ELISA MAX Deluxe was purchased from Biolegend; Ready-SET-
Go! ELISA sets for human IL-13, mouse IL-5, and IL-13 were purchased from
eBioscience; and the amounts of cytokines were measured according to the
manufacturer’s instructions.
Measurement of Lung Function
Lung function was evaluated by direct measurement of lung resistance
and dynamic compliance in restrained, tracheostomized, mechanically
ventilated mice via the FinePointe RC system (Buxco Research Systems,
Wilmington, NC) under general anesthesia as described before (Kerzerho
et al., 2013).Collection of BAL Fluid and Lung Histology
Mice were euthanized after evaluation of lung function, the trachea was intu-
bated, lungs were washed three times with 1 ml of PBS, and cells were then
harvested as previously described (Kerzerho et al., 2013). Relative and abso-
lute cell numbers in the BAL were calculated by flow cytometry as described in
the Supplemental Experimental Procedures. After taking BAL, we created lung
histology slides as described previously (Kerzerho et al., 2013). Histology pic-
tures were acquired with a KeyenceBZ-9000 microscope (Keyence, Itasca, IL)
and analyzed with the BZ-II Image Analysis Application (Keyence, Itasca, IL).
Gene Expression Analysis with Nanostring nCounter Technology
The difference in the abundance of scripts between the purified Icos/ and
WT ILC2s was analyzed with Nonostring nCounter technology as described
in the Supplemental Experimental Procedures. Heat plots were generated
with R statistical software.
Statistical Analysis
Experiments were repeated at least three times (n = 4–6 each), and data are
representative of three independent experiments. AHR data were analyzed
by repeated-measurements with the general linear model. All other data
were analyzed with JMP statistical software (Cary, NC) by Student’s t-tests
and confirmed by a Mann–Whitney U test. For multi-group comparisons, we
used one-way ANOVA with the Bonferroni post-hoc test.
SUPPLEMENTAL INFORMATION
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